Skip to main content

Table 1 Patient characteristics

From: Genetic polymorphism in ATG16L1 gene is associated with adalimumab use in inflammatory bowel disease

  Total
N = 570
CD
N = 411
UC
N = 148
IBDU
N = 11
Follow-up
 Length, mean, range 9.2 yrs (range 0.1–49.1) 9.5 yrs (range 0.1–49.1) 8.6 yrs (range 0.2–32.3) 4.9 yrs (range 0.8–10.5)
 Length, median 6.9 yrs 7.0 yrs 6.9 yrs 4.8 yrs
Gender
 Male 258 (45.3) 169 (41.1) 85 (57.4) 4 (36.4)
 Female 312 (54.7) 242 (58.9) 63 (42.6) 7 (63.6)
Age at diagnosis
 Mean, range 27 yr (range 5–79) 27 yr (range 5–79) 28 yr (range 8–69) 32 yr (range 17–47)
 Median 25 yr 25 yr 26 yr 32 yr
Disease location CD
 L1—terminal ileum   99 (24.1)   
 L2—colon   90 (21.9)   
 L3—ileocolon   120 (29.2)   
 (+) L4—upper GI tract   63 (15.3)   
 Other   0 (0)   
 Unknown   21 (5.1)   
 No inflammation   18 (4.4)   
Disease location UC
 E1—proctitis 8 (5.0)   7 (4.7) 1 (9.1)
 E2—left sided colitis 69 (43.4)   64 (43.2) 5 (45.4)
 E3—pancolitis 73 (45.9)   69 (46.6) 4 (36.4)
 No inflammation 3 (1.9)   3 (2.0) 0 (0)
 Other 2 (1.3)   1 (0.7) 1 (9.1)
 Unknown 4 (2.5)   4 (2.7) 0
 Backwash ileitis 35   22 3
 Rectal sparing 19   16 1
Disease behaviour CD
 B1—luminal disease   126 (30.7)   
 B2—stenosis   89 (21.7)   
 B3—abscesses and/or fistula   181 (44.0)   
 P—perianal disease   144 (35.0)   
 Unknown   15 (3.6)   
 Extra-intestinal 172 (30.2) 134 (32.6) 36 (24.3) 2 (18.2)
Family history of IBD
 Yes 127 (22.3) 98 (23.8) 25 (16.9) 4 (36.4)
 No 380 (66.7) 267 (65.0) 108 (73.0) 5 (45.4)
 Not documented 63 (11.0) 46 (11.2) 15 (10.1) 2 (18.2)
Family history of CRC
 Yes 36 (6.3) 22 (5.4) 13 (8.8) 1 (9.1)
 No 469 (82.3) 342 (83.2) 119 (80.4) 8 (72.7)
 Not documented 65 (11.4) 47 (11.4) 16 (10.8) 2 (18.2)
  1. All numbers are presented as n (%), unless stated otherwise
  2. CD Crohn’s disease, UC ulcerative colitis, IBDU unclassified inflammatory bowel disease, CRC colorectal cancer, IBD inflammatory bowel disease, yrs years